文献速递白血病

西班牙裔青少年和青年急性淋巴细胞白血病患者在试验入组和结局方面的差异

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

该研究为CALGB 10403研究的二次分析,评估西班牙裔青少年和青年急性淋巴细胞白血病患者的结局与地理入组模式。CALGB 10403入组295例患者(2007-2012年),其中45例(17%)为西班牙裔。西班牙裔患者3年总生存率为75%,与非西班牙裔白人患者的74%相比无显著差异(P=NS),且方案完成率更高(P=0.05)。

要点

  • CALGB 10403中西班牙裔患者3年OS为75%,非西班牙裔白人为74%,无显著差异(P=NS)。
  • 西班牙裔患者方案完成率更高(P=0.05)。
  • 试验入组地理分布与疾病流行病学不匹配,仅15%入组者来自西班牙裔AYA ALL高比例州。

核心结论

  • 在CALGB 10403中治疗的西班牙裔患者结局与非西班牙裔白人相当,且优于人群估计。
  • 试验地点与疾病流行病学的地理错位可能部分解释西班牙裔AYA ALL患者入组低于预期。

研究设计与样本

  • CALGB 10403研究的二次分析,纳入2007-2012年入组的295例AYA ALL患者。
  • 使用人口学、临床和生存数据,并与US人群数据(SEER注册中心、北美癌症注册协会)比较。

主要发现

  • 295例入组患者中263例(89%)报告了族裔/种族:西班牙裔45例(17%),非西班牙裔白人172例(65%),非西班牙裔黑人25例(10%),其他21例(8%)。
  • 与NHW相比,西班牙裔和NHB患者家庭收入更低,西班牙裔患者更可能携带高危CRLF2异常。
  • 美国估计中西班牙裔占新诊断AYA ALL患者的46%且OS劣于NHW(P<.001);CALGB 10403中西班牙裔AYA与NHW结局相当(3年OS 75% vs 74%;P=NS)。
  • 西班牙裔患者方案完成率更高(P=.05)。
  • CALGB 10403入组地域分布与美国西班牙裔AYA ALL分布不同:中西部入组最高,仅15%入组者来自西班牙裔AYA ALL患者高比例州。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic enrollment patterns relative to US population data. We used demographic, clinical, and survival data on AYAs enrolled on CALGB 10403 (N = 295, 2007-2012). Surveillance, Epidemiology, and End Results registries provided overall survival (OS) for US AYA ALL by ethnicity/race. North American Association of Cancer Registries provided AYA ALL incidence overall and proportion among Hispanics by US state. Of AYAs enrolled on CALGB 10403, 263 (89%) reported ethnicity/race: 45 (17%) Hispanic, 172 (65%) non-Hispanic White (NHW), 25 (10%) non-Hispanic Black (NHB), and 21 (8%) other. Compared with NHWs, Hispanic and NHB patients had lower household income, and Hispanic patients were more likely to harbor high-risk CRLF2 aberrations. Relative to US estimates, where Hispanic patients represented 46% of newly diagnosed AYA ALL patients and experienced inferior OS compared with NHW (P < .001), Hispanic AYAs on CALGB 10403 did as well as NHW patients (3 year OS, 75% vs 74%; P = NS). Hispanic patients also had higher rates of protocol completion (P = .05). Enrollments on CALGB 10403 differed relative to the distribution of Hispanic AYA ALL in the United States: enrollment was highest in the Midwest; t and only 15% of enrollees were from states with a high proportion of Hispanic AYA ALL patients. In summary, Hispanic patients treated on CALGB 10403 did as well as NHWs and better than population estimates. Geographical misalignment between trial sites and disease epidemiology may partially explain the lower-than-expected enrollment of Hispanic AYA ALL patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Muffly L, Yin J, Jacobson S, et al. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 35838753. doi:10.1182/bloodadvances.2022007197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。